We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

By LabMedica International staff writers
Posted on 11 Aug 2020
A genomics-based blood test can predict likelihood that a baby suffering hypoxia at birth will suffer serious nervous disorders such as cerebral palsy or epilepsy at a later stage of development.

Hypoxic ischemic encephalopathy has many causes and is essentially the reduction in the supply of blood or oxygen to a baby's brain before, during, or even after birth. More...
It is a major cause of death and disability, occurring in approximately two to three per 1000 births and causing around 20% of all cases of cerebral palsy.

Brain hypothermia, induced by cooling a baby to around 33 degrees Celsius for three days after birth, is a treatment for hypoxic ischemic encephalopathy. It has recently been proven to be the only medical intervention which reduces brain damage, and improves an infant's chance of survival and reduced disability.

Since a rapid and early diagnostic test to identify the encephalopathic babies at risk of adverse outcome has been lacking, investigators at Imperial College London (United Kingdom) have developed one.

The investigators theorized that a whole blood transcriptomic signature measured soon after birth would predict adverse neurodevelopmental outcome eighteen months after neonatal encephalopathy. To test this hypothesis, they performed next generation sequencing (NGS) on whole blood ribonucleic acid obtained within six hours of birth from the first 47 encephalopathic babies recruited to the Hypothermia for Encephalopathy in Low and middle-income countries (HELIX) trial. The study was conducted in Indian hospitals, where there are around 0.5-1.0 million cases of birth asphyxia per year. Blood was taken within six hours after birth, and the infants were followed until 18 months of age to identify those who developed neurodisabilities. Two infants with blood culture positive sepsis were excluded, and the data from remaining 45 were analyzed.

Results revealed that a total of 855 genes were significantly differentially expressed between the good and adverse outcome groups, of which Regulator of G-protein Signaling 1 (RGS1) and Structural Maintenance of Chromosomes Protein 4 (SMC4) were the most significant. Biological pathway analysis adjusted for gender, treatment (cooling therapy versus usual care), and estimated blood leukocyte proportions revealed over-representation of genes from pathways related to melatonin and polo-like kinase in babies with adverse outcome.

Senior author Dr. Sudhin Thayyil, professor of perinatal neuroscience at Imperial College London, said, "The results from these blood tests will allow us to gain more insight into disease mechanisms that are responsible for brain injury and allow us to develop new therapeutic interventions or improve those which are already available."

The study was published in the August 4, 2020, online edition of the journal Scientific Reports.


Related Links:

Imperial College London


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.